全球影像生物標記市場規模、佔有率、趨勢及成長分析報告（2026-2034）

全球影像生物標記市場預計將從2025年的188.3億美元成長至2034年的554.5億美元，2026年至2034年的複合年成長率（CAGR）為12.75%。全球醫療機構對先進影像技術的日益普及推動了該市場的強勁成長。影像生物標記在腫瘤學、神經病學和循環系統等領域的疾病檢測、治療方案製定和患者後續觀察中正發揮著至關重要的作用。精準醫療投入的增加、臨床研究活動的活性化以及人工智慧（AI）在影像工作流程中的應用，顯著提高了診斷的準確性和效率，從而推動了該行業在已開發國家和新興經濟體醫療體系中的持續擴張。

慢性疾病負擔日益加重以及對個人化治療方案的需求，是推動產業發展的主要動力。製藥公司越來越依賴影像生物標記來評估臨床試驗的治療效果，並改善藥物研發流程。醫院和診斷中心正在採用先進的影像平台，以實現更快、更可靠的診斷。政府對醫學研究的資助以及磁振造影（MRI）、電腦斷層掃描（CT）、正子斷層掃描（PET）和分子影像系統等技術的進步，進一步推動了整個產業的進步。

隨著醫療機構不斷採用數據驅動的診斷解決方案和非侵入性疾病監測技術，前景極為光明。機器學習、基於雲端的影像分析和數位病理學的進步有望提升生物標記的解讀和臨床決策水準。在罕見疾病、神經退化性疾病和精準腫瘤學等領域的應用拓展將創造更多機會。醫療設備製造商、研究機構和製藥公司之間的持續合作有望加速創新和長期商業化發展。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球影像生物標記市場：依生物標記分類

• 市場分析、洞察與預測
• 解剖學生物標記
• 功能性生物標記
• 分子和核生物標記
• 定量成像生物標記
• 其他

第5章 全球影像生物標記市場：依成像技術分類

• 市場分析、洞察與預測
• MRI
• CT
• PET
• SPECT
• 超音波
• 其他

第6章 全球影像生物標記市場：依應用分類

• 市場分析、洞察與預測
• 診斷
• 藥物發現與開發
• 個人化醫療
• 疾病風險評估
• 其他

第7章 全球影像生物標記市場：依最終用途分類

• 市場分析、洞察與預測
• 醫院
• 診斷和影像中心
• 製藥和生物技術公司
• 其他

第8章 全球影像生物標記市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • F. Hoffmann-La Roche AG
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc
  • Siemens Healthineers AG
  • Hologic Inc
  • QIAGEN NV
  • Bio-Rad Laboratories Inc
  • PerkinElmer Inc
  • Brainomix Limited
  • IXICO Plc
  • Median Technologies SA

The global imaging biomarkers market size is expected to reach USD 55.45 Billion in 2034 from USD 18.83 Billion in 2025, growing at a CAGR of 12.75 during 2026-2034.This market is witnessing strong expansion due to the increasing use of advanced diagnostic imaging technologies across healthcare facilities worldwide. Imaging biomarkers are becoming essential for disease detection, treatment planning, and patient monitoring in areas such as oncology, neurology, and cardiology. Growing investments in precision medicine, rising clinical research activities, and the integration of artificial intelligence into imaging workflows are significantly enhancing diagnostic accuracy and efficiency, supporting continuous industry expansion across developed and emerging healthcare systems.

The growing burden of chronic diseases and the need for personalized treatment approaches are major factors driving industry development. Pharmaceutical companies increasingly rely on imaging biomarkers during clinical trials to evaluate therapeutic outcomes and improve drug development processes. Hospitals and diagnostic centers are adopting sophisticated imaging platforms to achieve faster and more reliable diagnoses. Government funding for medical research and technological advancements in MRI, CT, PET, and molecular imaging systems further strengthen overall industry progress.

Future prospects remain highly promising as healthcare providers continue adopting data-driven diagnostic solutions and non-invasive disease monitoring techniques. Advances in machine learning, cloud-based imaging analytics, and digital pathology are expected to improve biomarker interpretation and clinical decision-making. Expanding applications in rare diseases, neurodegenerative disorders, and precision oncology will create additional opportunities. Continuous collaboration between medical device manufacturers, research institutions, and pharmaceutical companies is expected to accelerate innovation and long-term commercial development.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Biomarkers

• Anatomical Biomarkers
• Functional Biomarkers
• Molecular/Nuclear Biomarkers
• Quantitative Imaging Biomarkers
• Others

By Imaging Technology

• MRI
• CT
• PET
• SPECT
• Ultrasound
• Others

By Application

• Diagnostics
• Drug Discovery & Development
• Personalized Medicine
• Disease Risk Assessment
• Others

By End Use

• Hospitals
• Diagnostic/Imaging Centers
• Pharmaceutical and Biotech Companies
• Others

COMPANIES PROFILED

• F. Hoffmann-La Roche AG, Abbott Laboratories, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Hologic Inc., QIAGEN N.V., Bio-Rad Laboratories Inc., PerkinElmer Inc., Brainomix Limited, IXICO plc, Median Technologies S.A.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL IMAGING BIOMARKERS MARKET: BY BIOMARKERS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Biomarkers
• 4.2. Anatomical Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Functional Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Molecular/Nuclear Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Quantitative Imaging Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL IMAGING BIOMARKERS MARKET: BY IMAGING TECHNOLOGY 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Imaging Technology
• 5.2. MRI Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. CT Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. PET Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. SPECT Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Ultrasound Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL IMAGING BIOMARKERS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Drug Discovery & Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Personalized Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Disease Risk Assessment Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL IMAGING BIOMARKERS MARKET: BY END USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End Use
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Diagnostic/Imaging Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Pharmaceutical and Biotech Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL IMAGING BIOMARKERS MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Biomarkers
  • 8.2.2 By Imaging Technology
  • 8.2.3 By Application
  • 8.2.4 By End Use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Biomarkers
  • 8.3.2 By Imaging Technology
  • 8.3.3 By Application
  • 8.3.4 By End Use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Biomarkers
  • 8.4.2 By Imaging Technology
  • 8.4.3 By Application
  • 8.4.4 By End Use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Biomarkers
  • 8.5.2 By Imaging Technology
  • 8.5.3 By Application
  • 8.5.4 By End Use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Biomarkers
  • 8.6.2 By Imaging Technology
  • 8.6.3 By Application
  • 8.6.4 By End Use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL IMAGING BIOMARKERS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 F. Hoffmann-La Roche AG
  • 10.2.2 Abbott Laboratories
  • 10.2.3 Thermo Fisher Scientific Inc
  • 10.2.4 Siemens Healthineers AG
  • 10.2.5 Hologic Inc
  • 10.2.6 QIAGEN N.V
  • 10.2.7 Bio-Rad Laboratories Inc
  • 10.2.8 PerkinElmer Inc
  • 10.2.9 Brainomix Limited
  • 10.2.10 IXICO Plc
  • 10.2.11 Median Technologies S.A